Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Ken OgasawaraSimon ZhouGopal KrishnaMaria PalmisanoYan LiPublished in: Cancer chemotherapy and pharmacology (2019)
These results should serve as the basis for dose adjustment of fedratinib for special populations.
Keyphrases